Glucocorticoid Use

Cross-source consensus on Glucocorticoid Use from 1 sources and 3 claims.

1 sources · 3 claims

Benefits

Mean concomitant glucocorticoid dose decreased by 2 mg/day from baseline to month 24 during tofacitinib therapy. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
The percentage of patients using concomitant glucocorticoids fell from 62% at baseline to 46% at month 24. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
Increasing glucocorticoid dose during the study was associated with a higher likelihood of treatment step-up or switch, suggesting it functions as a marker of insufficient disease control. — Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)